FFC#16/2017

Pre-clinical effectiveness of three human cryptic antibiofilm peptides (GVF27, HVA36 and IMY47): efficacy against lung pathogens and studies in animals

AREA 3 Bronchopulmonary infection

FFC#16/2017

Pre-clinical effectiveness of three human cryptic antibiofilm peptides (GVF27, HVA36 and IMY47): efficacy against lung pathogens and studies in animals
€ 0 still needed
0%
€ 26.000 goal

pRINCIPAL INVESTIGATOR

Eliodoro Pizzo (Dipartimento di Biologia, Università di Napoli Federico II)

Researchers

7

Category

AREA 3 Bronchopulmonary infection

Duration

1 year

Goal

€ 26.000

Funds raised

€ 26.000

Objectives

Pseudomonas aeruginosa infection becomes chronic in CF lung since bacteria tend to acquire mucoid phenotype and drug-resistant biofilm. New antibiofilm drugs are intensively studied and these researchers have identified in this area the natural protein fragments called Host Defence Peptides (HDPs), which are secreted from all multicellular eukaryotic organisms and represents an essential component of innate immunity. They have developed and optimized a bioinformatics tool that allows the localization of HDP-like sequences hidden (cryptic) in potential HDPs releasing proteins. By this approach, they identified three interesting HDPs (GVF27, IMY47 and HVA36) and now they will carry out experiments on CF Pseudomonas aeruginosa clinical strains, on epithelial bronchial cells and CF murine models; the aim is to verify their antimicrobial potency and antibiofilm properties, when used alone or in synergy with conventional antibiotics.

WHO ADOPTED THE PROJECT

Gruppo di Sostegno FFC di San Giovanni Rotondo

€ 10.000

Guadagnin srl

€ 8.000

Delegazione FFC di Reggio Calabria

€ 8.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches